INSM Insmed Inc

Insmed Inc. (NASDAQ:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today announced that it will present at this week�s C.E. Unterberg, Towbin (CEUT) Emerging Growth Opportunities Conference in New York City. The conference, to be held at the Mandarin Oriental Hotel in New York City, will run from Tuesday, July 10th through Thursday, July 12th. Dr. Geoffrey Allan, Ph.D., Insmed�s President and CEO, will make the presentation on Thursday, July 12th at 8:30 a.m.; the Company will also hold one-on-one meetings with investment firm representatives. A live video Webcast of the presentation will be available at the investor relations section of Insmed�s website, www.insmed.com. Dr. Allan said, �We are especially pleased to be participating in this year�s CEUT conference, because it gives us an ideal forum to present our dual strategy growth plan, based on our approved proprietary protein platform and the development and manufacture of follow-on biologics, to a crucial audience of investment managers and analysts. Insmed has a very timely story to tell, and we are glad to get this opportunity to tell it at such a high-visibility event.� About Insmed Insmed is a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs. For more information please visit www.insmed.com. Forward Looking Statements: This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the Company may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than the Company, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company�s Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.